Telehealth Giant Hims Plans to Test Men for Low Testosterone
The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances.
Headline and summary written by an AI model from the linked article; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story
Price data
| Time | Chance of yes |
|---|---|
| now | 95% |
| 21 Oct, 14:39 UTC | 95% |
| 21 Oct, 14:23 UTC | 89% |
| 20 Oct, 13:50 UTC | 84% |
The story so far
1 publisher has covered this in 1 article since 21 Oct 2026. Feed: All Latest published first, on 21 October at 13:34 UTC.
One prediction market prices this story:
- Testosterone — the market puts it at 95%, closing 16 Nov 2026. The market resolves to Yes if any Hims & Hers Health representative mentions testosterone during their next earnings call, including the Q&A session. Otherwise, it resolves to No. Readers often mistake this for a requirement that testosterone be discussed in a specific context or by a particular individual, but the rule applies to any mention by any representative.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
Sources
Every article we clustered into this story. Headlines link to the publisher.
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi Testosterone 95%
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
In this story
- Hims